•Mirvetuximab soravtansine (MIRV) is used in the treatment of FRα positive, platinum-resistant epithelial ovarian cancer.•MIRV is associated with ocular events, leading to dose delays, dose reductions, and discontinuations of chemotherapy.•Mitigation strategies to prevent treatment disruption have historically relied on corticosteroid and lubricating drops.•Dehydrated amniotic membrane patch to treat MIRV related ocular events is a novel therapeutic option.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11617700 | PMC |
| http://dx.doi.org/10.1016/j.gore.2024.101547 | DOI Listing |
Publication Analysis
Top Keywords
amniotic membrane
8
membrane patch
8
ocular events
8
dehydrated amniotic
4
patch treatment
4
treatment ocular
4
ocular event
4
event secondary
4
secondary mirvetuximab
4
mirvetuximab soravtansine-gynx
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!